Drug intelligence / Profile preview

s095035

Development stage: Phase 2
Lead developer: Servier Bio-Innovation LLC
Modality: Small Molecules
Administration: Oral

Overview

S095035 is an orally bioavailable small molecule inhibitor of methionine adenosyltransferase 2A (MAT2A), currently under development by Servier Bio-Innovation. It is being investigated for its potential antineoplastic activity, specifically targeting advanced or metastatic solid tumors with homozygous deletion of the methylthioadenosine phosphorylase (MTAP) gene. The drug works by inhibiting MAT2A, an enzyme involved in the methionine cycle and essential for tumor cell survival in MTAP-deleted cancers. As of April 2025, S095035 is in Phase 1 clinical trials for oncology indications.

Other names: MAT2A inhibitor S-095035MAT-2A inhibitor S-095035MAT 2A inhibitor S-095035

Targets

MAT2A (Methionine adenosyltransferase 2A)

Beyond the preview

Go deeper on s095035.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on s095035.

Explore the full profile